Efficacy of individualised metacognitive therapy (MCT+) for delusions in psychosis

Not Applicable

Completed

• Conditions: schizophrenia spectrum disorders; delusions; Mental Health - Schizophrenia; Mental Health - Psychosis and personality disorders

• Registration Number: ACTRN12616000976482
• Lead Sponsor: Flinders University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-07-25
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

a) Must have a DSM-5 diagnosis of a schizophrenia spectrum disorder (this will be confirmed by the ‘Psychotic Disorder’ subscale of the Mini-International Neuropsychiatric Interview or M.I.N.I).

b) Must hold mild to moderate delusional beliefs as a minimum; this will be confirmed by a baseline ‘Delusions’ subscale score >3 of the Positive and Negative Syndrome Scale (PANSS).

c) Must be able to speak, read and understand English and have the ability to respond to questions and follow instructions.

Exclusion Criteria

a) primary diagnosis of substance use disorder
b) IQ<70
c) severe organic brain disorders

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Delusional severity as assessed by mean Positive and Negative Syndrome Scale (PANSS) P1 item (Delusions).[Baseline, 6-week follow-up (post commencement of intervention; T1), 6-month follow-up (post 6-week follow-up; T2)];Delusional severity as assessed by mean Psychotic Symptom Rating Scales (PSYRATS) delusion subscale total score.[Baseline, 6-week follow-up (post commencement of intervention; T1), 6-month follow-up (post 6-week follow-up; T2)]

Secondary Outcome Measures

Name	Time	Method
Brief Assessment of Cognition in Schizophrenia (BACS) will be used to assess various cognitive domains (e.g., working memory, verbal learning, reasoning and problem-solving, processing speed). [Baseline, 6-week follow-up (post commencement of intervention; T1), 6-month follow-up (post 6-week follow-up; T2)];Clinical insight will be assessed with the Schedule for Assessment of Insight<br>[Baseline, 6-week follow-up (post commencement of intervention; T1), 6-month follow-up (post 6-week follow-up; T2)];Cognitive insight will be assessed with the Beck Cognitive Insight Scale (i.e., measures of self-certainty and self-reflectiveness)[Baseline, 6-week follow-up (post commencement of intervention; T1), 6-month follow-up (post 6-week follow-up; T2)]